NCT05389267Active, not recruitingPhase 1/2
Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
Source: ClinicalTrials.gov · Last updated 7 Feb 2024
Brief summary (registry, in English)
The study purpose is to evaluate the safety of T4090.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 18 May 2022
- Start date
- 5 Jul 2022
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- Laboratoires Thea
- Diseases
- Glaucoma, High blood pressure
- NCT number
- NCT05389267
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 120
- From 5 Jul 2022 to the primary completion date, 31 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of trauma, infection, clinically significant inflammation within the previous 6 months
Other illness
- Known or suspected hypersensitivity to one of the components of the Investigational Medicinal Product(s)
Other
- Pregnancy or breast-feeding
Who the study is looking for
- Informed consent dated and signed.
- Both eyes diagnosed open-angle glaucoma or ocular hypertension
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dr EL-HARAZI Coordinator of this site? Confirm its status | Glendale | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.